For decades, the Medical Representative has been the backbone...

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

The future in your palm - a non-contact wearable...

The pharmaceutical industry in India is a rapidly evolving...

Brand Building Special Issue with articles on personal branding, brand differentiation and avoiding brand arrogance

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive...

The story of Healthium is not just one of...

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive...

The story of Healthium is not just one of...

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive...

The story of Healthium is not just one of...

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive...

The story of Healthium is not just one of...